Company intelligence / Profile preview

Genosco

Boston, Massachusetts, United Statesgenosco.com ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

Genosco’s most advanced asset, lazertinib, is an EGFR inhibitor for NSCLC. It has received regulatory approval in Korea for first and second-line therapy, with FDA approval in the US as of August 2024 and EU EC approval as of December 2024. The company also has multiple programs at preclinical to clinical stages targeting various autoimmune diseases, fibrosis, cancer/immuno-oncology indications, and CNS disorders. Their G-SMART™ platform underpins their pipeline by enabling rapid discovery of selective kinase inhibitors.

Therapeutic areas: GastroenterologyPulmonologyImmunologyDermatologyHematologyOncologyNeurology
Modalities: Small moleculesKinase inhibitors
Industry: Biotech

Drug pipeline

1 asset

GNS-3545

Partnerships

Janssen

Beyond the preview

Go deeper on Genosco.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genosco.

Explore the full profile